Sabinsa Founder Dr. Muhammed Majeed Publishes Fourth Book on Boswellia

Sami-Sabinsa Group

"The vision of a research scientist and a passionate entrepreneur takes on social and commercial expressions." This, in short, explains the genesis and growth of Sami-Sabinsa Group.

Sami-Sabinsa Group is a research-focused multinational health science company that was founded in 1991 by the late Dr. Muhammed Majeed, an internationally renowned scientist and entrepreneur in the field of evidence-based medicine. The company is a leading manufacturer of nutraceuticals and cosmeceutical ingredients, standardized herbal extracts, enzymes, probiotics, nutricosmetics, nutritional fine chemicals, and specialty chemicals.
Read More...

Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group

Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group has recently published the fourth book in a series on derivatives of Boswellia serrata.

Boswellin^®- Anti-Inflammatory Adaptogen from Nature was edited by Dr. Majeed and Dr. N. Kalyanam, and written by other senior scientists of Sami-Sabinsa Group. This new book on Boswellia captures the quintessential science on Boswellic acids, and breaks new ground by delving into the long-ignored polysaccharide component of Boswellia gum.

Boswellic acids are obtained from the gum resin of Boswellia serrata tree, a large, branching, deciduous tree which grows abundantly in the dry, hilly parts of India. It is known as Dhup, Indian frankincense, or Indian olibanum. The gum resin exudate of Boswellia serrata, known in the vernacular as “Salai guggal”, has been in use in Ayurvedic system of medicine for the management of rheumatism, respiratory diseases, and liver disorders. The primary use of Boswellia serrata in contemporary medicine is as an anti-arthritic and anti-inflammatory pharmacological agent.

The Boswellin^® range of Boswellia serrata extracts was introduced by Sami-Sabinsa Group to the nutritional industry in 1990’s. Sami-Sabinsa recognized the unique anti-inflammatory benefits of Boswellic acids, the active components of Boswellia, by their reported LOX inhibition, a subject of intense interest for three decades. Boswellin^® PS is an inclusive nutritional ingredient composed of both Boswellic acids and polysaccharide of the gum (Polysal^®).

“With many botanicals, there is so much more to study than the primarily-known active constituents,” said Dr. Majeed. “In studying Boswellia, we’ve made some intriguing discoveries about the immunomodulatory polysaccharides of Boswellia gum, and are eager to share those more widely.

To obtain a free copy of the book, email This email address is being protected from spambots. You need JavaScript enabled to view it. or ask your Sabinsa rep.

What We Do

Sami-Sabinsa Group Limited (formerly Sami Labs Limited), a pioneer and global leader in health science, is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, probiotics, and enzymes.

The company’s corporate R&D encompasses independent research divisions, including Natural Drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulation R&D. These divisions collaborate in a synergistic work model to produce products that adhere to international standards.

With the collective wisdom of over 120 research scientists, Sami-Sabinsa Group has developed standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe.